Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors

(2018) Alberto L. Horenstein et al.   Frontiers in Pharmacology

Targeting adenosine for cancer immunotherapy

(2018) Robert D. Leone et al.   Journal for ImmunoTherapy of Cancer

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients

(2018) Anne-Marit Sponaas et al.   Oncotarget

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

(2016) Alberto L Horenstein et al.   MOLECULAR MEDICINE

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years

(2015) Manabu Fujisawa et al.   ANNALS OF HEMATOLOGY

Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors

(2015) Sang-Yong Lee et al.   BIOCHEMICAL PHARMACOLOGY

Impact of interferon-  on hematopoiesis

(2014) A. M. de Bruin et al.   BLOOD

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia

(2014) Nashwa Khairat Abousamra et al.   LEUKEMIA & LYMPHOMA

Adenosine production by human B cells and B cell-mediated suppression of activated T cells

(2013) Z. Saze et al.   BLOOD

Adenosine receptors as drug targets — what are the challenges?

(2013) Jiang-Fan Chen et al.   NATURE REVIEWS DRUG DISCOVERY

Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma

(2013) Xiao-Xia Lu   WORLD JOURNAL OF GASTROENTEROLOGY

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes

(2013) Alberto L Horenstein et al.   OncoImmunology

Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes

(2011) Felipe Saldanha-Araujo et al.   Stem Cell Research

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

(2010) S Colla et al.   LEUKEMIA

Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation

(2009) Courtney M. Lappas et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function

(2008) Balázs Csóka et al.   FASEB JOURNAL

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

(2008) György Haskó et al.   NATURE REVIEWS DRUG DISCOVERY

The novel NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP breakdown but also blocks central synaptic transmission, an action independent of NTPDase inhibition

(2008) Mark J. Wall et al.   NEUROPHARMACOLOGY